[Pharm-policy] Gene Pill Platform Receives Broad Patent Coverage

[love@cptech.org]

http://www.uventures.com/servlets/UVTechNews/2837


 Gene Pill Platform Receives Broad Patent Coverage 
 
Genteric, Inc., announced it has received a Notice of Allowance from the
U.S. Patent Office that will extend the intellectual property coverage
for its Gene Pill technology platform to include all secreted proteins.

This allowance follows the recent patent that the company was issued
(U.S. Patent 6,225,290 entitled "Systemic Gene Therapy By Intestinal
Cell Transformation), which gave Genteric claim to the delivery of the
human insulin gene, using the Gene Pill Platform. The new patent
significantly extends the coverage of the existing technology.

Genterics Gene Pill technology enables the oral administration of an
engineered gene that encodes a therapeutic protein. The gene is taken up
by cells of the intestine, which then produce the protein. Once the
protein is produced, it is secreted into the patients bloodstream
providing the desired therapeutic effect. This revolutionary approach
has the potential to replace many of the current array of injectable
protein drugs.

   [snip]